tiprankstipranks
Trending News
More News >
Vericel Corp (VCEL)
NASDAQ:VCEL
US Market

Vericel (VCEL) Earnings Dates, Call Summary & Reports

Compare
588 Followers

Earnings Data

Report Date
Jul 30, 2025
TBA Not Confirmed
Period Ending
2025 (Q2)
Consensus EPS Forecast
-0.02
Last Year’s EPS
-0.1
Same Quarter Last Year
Based on 7 Analysts Ratings
---

Earnings Call Summary

Earnings Call Date:May 08, 2025
|
% Change Since: -23.42%
|
Next Earnings Date:Jul 30, 2025
Earnings Call Sentiment|Positive
The earnings call highlighted strong revenue performance and promising growth from new product launches such as MACI Arthro. Despite challenges in Epicel revenue and increased operating expenses leading to a net loss, the company maintains a positive outlook with reaffirmed and raised financial guidance, driven by strong cash flow and strategic growth initiatives.
Company Guidance
In the Vericel Corporation's first quarter 2025 earnings call, guidance was provided with several key metrics highlighted. The company projected strong second quarter performance with total revenue growth expected to be between 22% and 25%, amounting to approximately $64 million to $66 million. For the full year, Vericel reaffirmed its revenue growth guidance of 20% to 23% and raised its profitability guidance. MACI achieved record first quarter revenue of over $46 million, with an anticipated second quarter revenue growth of 22% to 24%. NexoBrid revenue increased by over 200% year-over-year and 31% sequentially, while Epicel revenue showed potential for significant improvement in the second quarter despite a first-quarter shortfall. The gross margin is expected to be in the low 70% range for the second quarter, with an adjusted EBITDA margin of 20%. For the full year, the company raised its gross margin guidance to 75% and adjusted EBITDA margin guidance to 26%. Additionally, plans for a MACI sales force expansion were discussed, aimed at supporting continued growth.
Record First Quarter Revenue
Vericel achieved record first quarter revenue, with MACI revenue surpassing $46 million, driven by strong underlying fundamentals and expansion of the MACI surgeon customer base.
Strong MACI Arthro Launch
The MACI Arthro launch shows significant strength, with trained surgeons driving over 30% biopsy growth. Approximately 400 MACI Arthro surgeons have been trained, surpassing the pace of the 2017 MACI launch.
NexoBrid Revenue Growth
NexoBrid revenue increased over 200% compared to the previous year and over 30% sequentially, with a higher proportion of business from consistent ordering centers.
Positive Financial Guidance
Vericel reaffirms full-year revenue guidance of 20% to 23% growth and raises profitability guidance, expecting a strong second quarter with total company revenue growth of 22% to 25%.
Strong Cash Position
The company generated $6.6 million in operating cash flow and ended the quarter with $162 million in cash, restricted cash, and investments, with no debt.
---

Vericel (VCEL) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

VCEL Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Jul 30, 20252025 (Q2)
-0.02 / -
-0.1
May 08, 20252025 (Q1)
-0.12 / -0.23
-0.08-187.50% (-0.15)
Feb 27, 20252024 (Q4)
0.32 / 0.38
0.2646.15% (+0.12)
Nov 07, 20242024 (Q3)
-0.05 / -0.02
-0.0875.00% (+0.06)
Aug 01, 20242024 (Q2)
-0.09 / -0.10
-0.119.09% (<+0.01)
May 08, 20242024 (Q1)
-0.11 / -0.08
-0.1650.00% (+0.08)
Feb 29, 20242023 (Q4)
0.17 / 0.26
0.12116.67% (+0.14)
Nov 08, 20232023 (Q3)
-0.12 / -0.08
-0.1442.86% (+0.06)
Aug 02, 20232023 (Q2)
-0.15 / -0.11
-0.1942.11% (+0.08)
May 10, 20232023 (Q1)
-0.15 / -0.16
-0.15-6.67% (-0.01)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---

VCEL Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Feb 27, 2025$52.85$49.62-6.11%
Nov 07, 2024$48.04$50.03+4.14%
Aug 01, 2024$50.52$47.52-5.94%
May 08, 2024$49.52$47.69-3.70%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---

FAQ

When does Vericel Corp (VCEL) report earnings?
Vericel Corp (VCEL) is schdueled to report earning on Jul 30, 2025, TBA Not Confirmed.
    What is Vericel Corp (VCEL) earnings time?
    Vericel Corp (VCEL) earnings time is at Jul 30, 2025, TBA Not Confirmed.
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is VCEL EPS forecast?
          VCEL EPS forecast for the fiscal quarter 2025 (Q2) is -0.02.
            ---
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis